TY - JOUR
T1 - Translocation renal cell carcinomas
T2 - an evolving entity and a member of the microphthalmia transcription factor-associated family of tumors
AU - Bambury, Richard M.
AU - Battley, Jodie E.
AU - McCarthy, Aoife
AU - Brady, Claire
AU - O'Reilly, Seamus
AU - Kelly, Paul J.
AU - O'Brien, Frank
AU - Sweeney, Paul
AU - Fleming, Stewart
AU - Mayer, Nick J.
AU - Power, Derek G.
PY - 2013/9
Y1 - 2013/9
N2 - Translocation renal cell carcinomas (tRCC) are a novel, rare, and distinct clinicopathologic entity first described in 2001. They are caused by genetic translocations which fuse transcription factor genes, TFE3 or TFEB, with a promoter region leading to overexpression of the transcription factor. TFE3 and TFEB are members of the MiT family of transcription factors. Other tumors also driven by overexpression of members of the MiT family include alveolar soft part sarcoma, clear cell sarcoma and 30%-40% of melanomas. Recently some authors have suggested classifying these tumors along with tRCC as the 'MiT family of cancers.' We report 3 cases of this rare subtype of renal cell carcinoma and provide an up to date literature review of the topic. This report highlights the clinical and pathologic heterogeneity of these tumors. Efforts are under way to find a therapy to target the gene fusion products or their downstream effectors which drive growth of these tumors.
AB - Translocation renal cell carcinomas (tRCC) are a novel, rare, and distinct clinicopathologic entity first described in 2001. They are caused by genetic translocations which fuse transcription factor genes, TFE3 or TFEB, with a promoter region leading to overexpression of the transcription factor. TFE3 and TFEB are members of the MiT family of transcription factors. Other tumors also driven by overexpression of members of the MiT family include alveolar soft part sarcoma, clear cell sarcoma and 30%-40% of melanomas. Recently some authors have suggested classifying these tumors along with tRCC as the 'MiT family of cancers.' We report 3 cases of this rare subtype of renal cell carcinoma and provide an up to date literature review of the topic. This report highlights the clinical and pathologic heterogeneity of these tumors. Efforts are under way to find a therapy to target the gene fusion products or their downstream effectors which drive growth of these tumors.
UR - http://www.scopus.com/inward/record.url?scp=84883356834&partnerID=8YFLogxK
U2 - 10.1016/j.clgc.2012.12.006
DO - 10.1016/j.clgc.2012.12.006
M3 - Article
C2 - 23332637
AN - SCOPUS:84883356834
SN - 1558-7673
VL - 11
SP - 357
EP - 361
JO - Clinical Genitourinary Cancer
JF - Clinical Genitourinary Cancer
IS - 3
ER -